Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;198(12):1116-1118.
doi: 10.1007/s00066-022-01990-7. Epub 2022 Aug 11.

[Monotherapy with immune checkpoint blockade leads to clinical complete remission in patients with rectal cancer and microsatellite instability]

[Article in German]
Markus Diefenhardt  1 , Emmanouil Fokas  1 , Claus Rödel  2
Affiliations
Comment

[Monotherapy with immune checkpoint blockade leads to clinical complete remission in patients with rectal cancer and microsatellite instability]

[Article in German]
Markus Diefenhardt et al. Strahlenther Onkol. 2022 Dec.
No abstract available

PubMed Disclaimer

Comment on

  • PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. Cercek A, et al. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660797 Free PMC article. Clinical Trial.

References

    1. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363–2376. doi: 10.1056/NEJMoa2201445. - DOI - PMC - PubMed
    1. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566–576. doi: 10.1038/s41591-020-0805-8. - DOI - PubMed
    1. Diaz LA, Jr., Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659–670. doi: 10.1016/S1470-2045(22)00197-8. - DOI - PMC - PubMed
    1. Trojan J, Stintzing S, Haase O, et al. Complete pathological response after neoadjuvant short-course immunotherapy with Ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist. 2021;26:e2110–e2114. doi: 10.1002/onco.13955. - DOI - PMC - PubMed
    1. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649–1654. doi: 10.1038/s41591-018-0197-1. - DOI - PMC - PubMed